Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.50
Bid: 9.30
Ask: 9.50
Change: -0.35 (-3.59%)
Spread: 0.20 (2.151%)
Open: 9.55
High: 10.00
Low: 9.50
Prev. Close: 9.75
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Mar 2015 14:22

RNS Number : 8081G
e-Therapeutics plc
06 March 2015
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

e-Therapeutics plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

 

3. Full name of person(s) subject to thenotification obligation:

Henderson Global Investors

4. Full name of shareholder(s) (if different from 3.):

 

5. Date of the transaction and date onwhich the threshold is crossed orreached: 

5 March 2015

6. Date on which issuer notified:

6 March 2015

7. Threshold(s) that is/are crossed orreached:

Above 10%

     
 

 

8. Notified details:

A: Voting rights attached to shares 

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights

Direct

Direct 

Indirect 

Direct

Indirect

Ordinary

17,539,408

17,539,408

 

 

 

26,640,299

 

 

 

 

10.07%

GB00B2823H99

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate 

Exercise/Conversion Period 

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments 

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date

Exercise/Conversion period

Number of voting rights instrument refers to

 

% of voting rights 

 

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

26,640,299

10.07%

                 
 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

 

 

Proxy Voting:

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will ceaseto hold:

 

12. Date on which proxy holder will cease to holdvoting rights:

 

 

13. Additional information:

 

This disclosure has been calculated based on issue share capital amount 264,362,821.

 

14. Contact name:

Scott Dickenson

15. Contact telephone number:

020 7818 4184

   

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEALDKEFPSEFF
Date   Source Headline
2nd Jan 20203:28 pmRNSDirector/PDMR Shareholding
8th Nov 201910:54 amRNSHolding(s) in Company
29th Oct 20194:10 pmRNSHolding(s) in Company
28th Oct 20192:36 pmRNSHolding(s) in Company
28th Oct 201912:05 pmRNSHolding(s) in Company
28th Oct 20198:00 amRNSHolding(s) in Company
7th Oct 20197:00 amRNSHalf-year Report
17th Sep 20194:41 pmRNSHolding(s) in Company
4th Sep 20192:05 pmRNSSecond Price Monitoring Extn
4th Sep 20192:00 pmRNSPrice Monitoring Extension
4th Sep 201911:05 amRNSSecond Price Monitoring Extn
4th Sep 201911:00 amRNSPrice Monitoring Extension
23rd Aug 201911:21 amRNSHolding(s) in Company
22nd Aug 201911:42 amRNSHolding(s) in Company
13th Aug 20197:00 amRNSe-therapeutics to work with top pharma company
1st Aug 20197:00 amRNSExtends Research Collaboration with Novo Nordisk
15th Jul 20192:06 pmRNSSecond Price Monitoring Extn
15th Jul 20192:00 pmRNSPrice Monitoring Extension
2nd Jul 20197:00 amRNSDirector/PDMR Shareholding
28th Jun 20192:06 pmRNSSecond Price Monitoring Extn
28th Jun 20192:00 pmRNSPrice Monitoring Extension
27th Jun 20193:17 pmRNSHolding(s) in Company
26th Jun 20194:41 pmRNSHolding(s) in Company
6th Jun 20193:58 pmRNSHolding(s) in Company
30th Apr 201911:21 amRNSResult of AGM
2nd Apr 20197:00 amRNSDirector/PDMR Shareholding
29th Mar 201910:00 amRNSDirector/PDMR Shareholding
20th Mar 201911:05 amRNSSecond Price Monitoring Extn
20th Mar 201911:00 amRNSPrice Monitoring Extension
14th Mar 201912:39 pmEQSEdison issues outlook on Jersey Electricity (JEL)
8th Mar 201910:30 amRNSNotice of Annual General Meeting and Annual Report
5th Mar 20193:51 pmEQSEdison issues update on e-Therapeutics (ETX)
5th Mar 20197:00 amRNSFull Year Results
20th Feb 20197:00 amRNSNotification of Full Year Results Date
3rd Jan 20199:00 amRNSDirector/PDMR Shareholding
12th Dec 20181:01 pmEQSEdison Investment Research Limited: Edison issues outlook on e-Therapeutics (ETX)
10th Dec 20187:00 amRNSResearch Collaboration Agreement with Novo Nordisk
6th Dec 201810:36 amEQSEdison Investment Research Limited: Edison issues update on e-Therapeutics (ETX)
6th Dec 20187:00 amRNSE-therapeutics and C4X Collaboration
29th Nov 20187:00 amRNSDrug Discovery Innovation Programme Presentation
12th Nov 201811:30 amRNSe-therapeutics to present at BioCentury Summit
5th Nov 20187:00 amRNSHolding(s) in Company
8th Oct 201810:42 amEQSEdison issues update on e-Therapeutics (ETX)
4th Oct 20187:00 amRNSInterim Results for six months ended 31 July 2018
17th Sep 201811:30 amRNSNotice of Interim Results
9th Aug 20187:00 amRNSDirector Shareholding
7th Aug 20187:00 amRNSDirector/PDMR Shareholding
3rd Jul 20182:08 pmRNSDirector/PDMR Shareholding
31st May 20182:13 pmRNSResults of Annual General Meeting
1st May 20187:00 amRNSCollaboration with C4X Discovery Holdings PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.